Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has 5 years of Gross Profit data on file, last reported at $6.4 million in Q1 2025.

• Gross Profit for Q1 2025 came in at $6.4 million, up 35.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.4 million (down 72.19% YoY), and the FY2025 annual result was $6.4 million, down 72.19% from the prior year.
• Gross Profit fell to $6.4 million in Q1 2025 per WHWK's latest filing, from $6.4 million in the prior quarter.
• Over five years, Gross Profit peaked at $14.0 million in Q4 2021 and troughed at $2.1 million in Q1 2022.
• A 5-year average of $5.6 million and a median of $5.4 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2023: Gross Profit plunged 64.25% in 2022, then soared 150.85% in 2023.
• A 5-year view of Gross Profit shows it stood at $14.0 million in 2021, then sank by 64.25% to $5.0 million in 2022, then gained by 7.87% to $5.4 million in 2023, then advanced by 19.45% to $6.4 million in 2024, then fell by 0.99% to $6.4 million in 2025.
• Business Quant data shows WHWK's Gross Profit at $6.4 million in Q1 2025, $6.4 million in Q4 2024, and $6.4 million in Q3 2024.